Investors

GA is a fast-growing molecular diagnostic company which uses its unique, patented and documented GA-map® technology to map gut microbiota by detecting and characterizing imbalance in the gut microbiota (dysbiosis) from human fecal samples. 

The market potential for our products is rapidly growing as the industry is seeing a change in the importance of relating gut microbiota to different diseases. We are therefore proud to be one of the world’s leading companies in the huge and growing market of gut microbiota mapping. 

GA is the first company in the world to develop, document, clinically validate and commercialize a CE-marked In Vitro Diagnostic test (GA-map® Dysbiosis Test Lx) for diagnosis and characterizing of dysbiosis in IBS and IBD patients. Our test has been used in 50 clinical trials and reported in 25+ scientific publications. In 2020 we have lunched the first CE-marked GA-map® COVID-19 fecal test. A Qualitative Real Time PCR test for the detecting of the 2019 novel coronavirus (SARS-CoV-2) RNA in stool samples.  

Top-10 Shareholders:

  • Bio-Rad Laboratories Inc. 
  • Nordnet Bank AB (nom)*
  • Biohit Oyj
  • Norsk Innovasjonskapital AS
  • Nordea Bank Abp (nom)*
  • Molver AS
  • Rolfs Holding AS
  • LJM AS
  • Norda ASA
  • Lucellum AS

Ronny Hermansen – CEO

Invest in GA?

Please contact me:
rh@genetic-analysis.com